{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T00:52:41Z","timestamp":1759366361609,"version":"build-2065373602"},"reference-count":56,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,9,1]],"date-time":"2005-09-01T00:00:00Z","timestamp":1125532800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["La Revue de M\u00e9decine Interne"],"published-print":{"date-parts":[[2005,9]]},"DOI":"10.1016\/j.revmed.2005.02.007","type":"journal-article","created":{"date-parts":[[2005,3,19]],"date-time":"2005-03-19T18:18:26Z","timestamp":1111256306000},"page":"717-724","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Spondylarthropathies et m\u00e9dicaments anti-TNF\u03b1"],"prefix":"10.1016","volume":"26","author":[{"given":"S.","family":"Pavy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Y.","family":"Allanore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Kahan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.revmed.2005.02.007_bib1","first-page":"85","article-title":"Crit\u00e8res de classification des spondylarthropathies","volume":"57","author":"Amor","year":"1990","journal-title":"Rev. Rhum. Mal. Osteoartic."},{"key":"10.1016\/j.revmed.2005.02.007_bib2","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","article-title":"Psoriatic arthritis","volume":"3","author":"Moll","year":"1973","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.revmed.2005.02.007_bib3","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1002\/1529-0131(199906)42:6<1080::AID-ANR2>3.0.CO;2-7","article-title":"Psoriatic arthritis. A unified concept twenty years on","volume":"42","author":"McGonagle","year":"1999","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.revmed.2005.02.007_bib4","first-page":"1401","article-title":"Rhumatisme psoriasique","volume":"129","author":"Allanore","year":"2002","journal-title":"Ann. Dermatol. Venereol."},{"key":"10.1016\/j.revmed.2005.02.007_bib5","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1002\/art.1780380507","article-title":"Sulfasalazine in the treatment of spondylarthropathy: a randomized, multicenter, double-blind, placebo-controlled study","volume":"38","author":"Dougados","year":"1995","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.revmed.2005.02.007_bib6","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1002\/1529-0131(199911)42:11<2325::AID-ANR10>3.0.CO;2-C","article-title":"Comparison of sulfasalazine and placebo for the treatment of axial and peripheral articular manifestations of the seronegative spondylarthropathies: a Department of Veterans Affairs cooperative study","volume":"42","author":"Clegg","year":"1999","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.revmed.2005.02.007_bib7","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1093\/rheumatology\/35.7.664","article-title":"Sulphasalazine in psoriatic arthritis: a randomized, multicentre, placebo-controlled study","volume":"35","author":"Combe","year":"1996","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.revmed.2005.02.007_bib8","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/sarh.2002.50024","article-title":"Effectiveness of psoriatic arthritis therapies","volume":"33","author":"Gladman","year":"2003","journal-title":"Semin. Arthritis Rheum."},{"key":"10.1016\/j.revmed.2005.02.007_bib9","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1002\/art.1780270403","article-title":"Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis","volume":"27","author":"Willkens","year":"1984","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.revmed.2005.02.007_bib10","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0002-9343(05)80060-9","article-title":"Methotrexate and histologic hepatic abnormalities: a meta-analysis","volume":"90","author":"Whiting-O'Keefe","year":"1991","journal-title":"Am. J. Med."},{"key":"10.1016\/j.revmed.2005.02.007_bib11","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/art.20253","article-title":"Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial","volume":"50","author":"Kaltwasser","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.revmed.2005.02.007_bib12","article-title":"A randomised, double-blind, placebo controlled, multi-centre trial of combination therapy with methotrexate plus cyclosporin in patients with active psoriatic arthritis","author":"Fraser","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.revmed.2005.02.007_bib13","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1056\/NEJM199905063401804","article-title":"Infliximab for the treatment of fistulas in patients with Crohn's disease","volume":"340","author":"Present","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.revmed.2005.02.007_bib14","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1002\/art.1780380407","article-title":"Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis","volume":"38","author":"Braun","year":"1995","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.revmed.2005.02.007_bib15","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/rheumatology\/33.10.927","article-title":"Serum cytokines (IL-6, TNF-alpha, IL-1 beta and IFN-gamma) in ankylosing spondylitis: a close correlation between serum IL-6 and disease activity and severity","volume":"33","author":"Gratacos","year":"1994","journal-title":"Br. J. Rheumatol."},{"key":"10.1016\/j.revmed.2005.02.007_bib16","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/BF00390264","article-title":"Serum levels of interleukin 1-beta, tumor necrosis factor-alpha, soluble interleukin 2 receptor and soluble CD8 in seronegative spondylarthropathies","volume":"13","author":"Toussirot","year":"1994","journal-title":"Rheumatol. Int."},{"issue":"Suppl 9","key":"10.1016\/j.revmed.2005.02.007_bib17","first-page":"S217","article-title":"Efficacy and safety of adalimumab in the treatment of active ankylosing spondylitis: preliminary results of an open-label, 20-week trial. American College of Rheumatology: 68th Annual Scientific Meeting","volume":"50","author":"Haibel","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2005.02.007_bib18","first-page":"2286","article-title":"A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index","volume":"21","author":"Garrett","year":"1994","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.revmed.2005.02.007_bib19","doi-asserted-by":"crossref","first-page":"1876","DOI":"10.1002\/1529-0131(200108)44:8<1876::AID-ART326>3.0.CO;2-F","article-title":"Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis","volume":"44","author":"Anderson","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.revmed.2005.02.007_bib20","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/S0140-6736(02)08215-6","article-title":"Treatment of active ankylosing spondylitis with infliximab\u00a0: a randomised controlled multicentre trial","volume":"359","author":"Braun","year":"2002","journal-title":"Lancet"},{"issue":"Suppl 9","key":"10.1016\/j.revmed.2005.02.007_bib21","first-page":"S217","article-title":"Clinical response to long-term therapy with infliximab in patients with ankylosing spondylitis \u2013 results after 3 years. American College of Rheumatology: 68th Annual Scientific Meeting","volume":"50","author":"Baraliakos","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2005.02.007_bib22","first-page":"959","article-title":"Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety","volume":"29","author":"Maksymowych","year":"2002","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.revmed.2005.02.007_bib23","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1093\/rheumatology\/41.11.1280","article-title":"Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month open-label study","volume":"41","author":"Breban","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.revmed.2005.02.007_bib24","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJMoa012664","article-title":"Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor \u03b1","volume":"346","author":"Gorman","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.revmed.2005.02.007_bib25","doi-asserted-by":"crossref","first-page":"1667","DOI":"10.1002\/art.11017","article-title":"Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis","volume":"48","author":"Brandt","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.revmed.2005.02.007_bib26","doi-asserted-by":"crossref","first-page":"3230","DOI":"10.1002\/art.11325","article-title":"Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial","volume":"48","author":"Davis","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.revmed.2005.02.007_bib27","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1136\/ard.2004.020875","article-title":"Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis","volume":"63","author":"Calin","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.revmed.2005.02.007_bib28","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/ard.2004.020503","article-title":"Assessment of outcome in ankylosing spondylitis: an extended radiographic scoring system","volume":"64","author":"Creemers","year":"2005","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.revmed.2005.02.007_bib29","first-page":"997","article-title":"Radiological scoring methods in ankylosing spondylitis: reliability and sensitivity to change over one year","volume":"26","author":"Spoorenberg","year":"1999","journal-title":"J. Rheumatol."},{"issue":"Suppl 9","key":"10.1016\/j.revmed.2005.02.007_bib30","first-page":"S450","article-title":"X-Ray progression in patients with ankylosing spondylitis (AS) after 2 years of infliximab therapy. American College of Rheumatology: 68th Annual Scientific Meeting","volume":"50","author":"Baraliakos","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2005.02.007_bib31","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1002\/1529-0131(200109)44:9<2112::AID-ART363>3.0.CO;2-H","article-title":"Efficacy of etanercept in the treatment of the entheseal pathology in resistant spondylarthropathy: a clinical and magnetic resonance imaging study","volume":"44","author":"Marzo-Ortega","year":"2001","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.revmed.2005.02.007_bib32","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1002\/art.10883","article-title":"Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis, before and after successful therapy with infliximab:evaluation of a new scoring system","volume":"48","author":"Braun","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.revmed.2005.02.007_bib33","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S0140-6736(00)02530-7","article-title":"Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial","volume":"356","author":"Mease","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.revmed.2005.02.007_bib34","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","article-title":"Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression","volume":"50","author":"Mease","year":"2004","journal-title":"Arthritis Rheum."},{"issue":"Suppl 9","key":"10.1016\/j.revmed.2005.02.007_bib35","first-page":"S450","article-title":"The Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT): results of radiographic analyses after 1 year. American College of Rheumatology: 68th Annual Scientific Meeting","volume":"50","author":"Antoni","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.revmed.2005.02.007_bib36","series-title":"American College of Rheumatology: 68th Annual Scientific Meeting. Program Book Suppl","first-page":"29","article-title":"Adalimumab therapy in patients with psoriatic arthritis: 24-week results of a phase III study","author":"Mease","year":"2004"},{"key":"10.1016\/j.revmed.2005.02.007_bib37","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1002\/art.511","article-title":"Randomized double-blind comparison of chimeric monoclonal antibody to tumor necrosis factor \u03b1 (infliximab) versus placebo in active spondylarthropathy","volume":"46","author":"Van den Bosch","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.revmed.2005.02.007_bib38","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/ard.61.3.207","article-title":"Repeated infusions of infliximab, a chimeric anti-TNF\u03b1 monoclonal antibody, in patients with active spondyloarthropathy: one year follow up","volume":"61","author":"Kruithof","year":"2002","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.revmed.2005.02.007_bib39","first-page":"531","article-title":"Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept","volume":"31","author":"Brandt","year":"2004","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.revmed.2005.02.007_bib40","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1002\/art.1780341003","article-title":"The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy","volume":"34","author":"Dougados","year":"1991","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.revmed.2005.02.007_bib41","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1002\/art.1780270401","article-title":"Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria","volume":"27","author":"Van der Linden","year":"1984","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.revmed.2005.02.007_bib42","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1136\/ard.62.9.829","article-title":"Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?","volume":"62","author":"Baeten","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.revmed.2005.02.007_bib43","unstructured":"Recommandations nationales sur la pr\u00e9vention et la prise en charge de la tuberculose survenant sous Remicade. AFSSAPS juillet 2004, consultable \u00e0 l\u2019adresse\u00a0: http:\/\/agmed.sante.gouv.fr\/htm\/10\/remicade\/reco.pdf."},{"key":"10.1016\/j.revmed.2005.02.007_bib44","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/art.10758","article-title":"Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents","volume":"48","author":"Slifman","year":"2003","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.revmed.2005.02.007_bib45","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1002\/art.10583","article-title":"Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept","volume":"46","author":"Lee","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.revmed.2005.02.007_bib46","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1136\/ard.2004.024737","article-title":"Anti-tumour necrosis factor \u03b1 therapy in rheumatoid arthritis: an update on safety","volume":"63","author":"Hyrich","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.revmed.2005.02.007_bib47","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1056\/NEJM200104053441415","article-title":"Invasive pulmonary aspergillosis associated with infliximab therapy","volume":"344","author":"Warris","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.revmed.2005.02.007_bib48","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jbspin.2004.03.003","article-title":"Induction des autoanticorps au cours des spondylarthropathies refractaires trait\u00e9es par infliximab en association au m\u00e9thotrexate","volume":"72","author":"Sellam","year":"2005","journal-title":"Joint Bone Spine"},{"key":"10.1016\/j.revmed.2005.02.007_bib49","doi-asserted-by":"crossref","first-page":"3151","DOI":"10.1002\/art.10679","article-title":"Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration","volume":"46","author":"Brown","year":"2002","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.revmed.2005.02.007_bib50","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1002\/art.20311","article-title":"Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients","volume":"50","author":"Wolfe","year":"2004","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.revmed.2005.02.007_bib51","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/art.20241","article-title":"Results from an open-label extension study of etanercept in ankylosing spondylitis","volume":"51","author":"Davis","year":"2004","journal-title":"Arthritis Rheum Arthritis Care Res"},{"key":"10.1016\/j.revmed.2005.02.007_bib52","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1136\/ard.2003.016386","article-title":"Prediction of a major clinical response (BASDAI 50) to tumour necrosis factor \u03b1 blockers in ankylosing spondylitis","volume":"63","author":"Rudwaleit","year":"2004","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.revmed.2005.02.007_bib53","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1136\/ard.62.9.817","article-title":"International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis","volume":"62","author":"Braun","year":"2003","journal-title":"Ann. Rheum. Dis."},{"key":"10.1016\/j.revmed.2005.02.007_bib54","first-page":"1356","article-title":"Canadian Rheumatology Association Consensus on the use of anti-tumor necrosis factor-\u03b1 directed therapies in the treatment of spondyloarthritis","volume":"30","author":"Maksymowych","year":"2003","journal-title":"J. Rheumatol."},{"key":"10.1016\/j.revmed.2005.02.007_bib55","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.1002\/1529-0131(200011)43:11<2383::AID-ANR2>3.0.CO;2-D","article-title":"Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor \u03b1: findings in open-label and randomized placebo-controlled trials","volume":"43","author":"Charles","year":"2000","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.revmed.2005.02.007_bib56","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1056\/NEJMoa020888","article-title":"Influence of immunogenicity on the long term efficacy of infliximab on Crohn\u2019s disease","volume":"348","author":"Baert","year":"2003","journal-title":"N. Engl. J. Med."}],"container-title":["La Revue de M\u00e9decine Interne"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866305000846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0248866305000846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T16:13:51Z","timestamp":1759335231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0248866305000846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,9]]},"references-count":56,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2005,9]]}},"alternative-id":["S0248866305000846"],"URL":"https:\/\/doi.org\/10.1016\/j.revmed.2005.02.007","relation":{},"ISSN":["0248-8663"],"issn-type":[{"type":"print","value":"0248-8663"}],"subject":[],"published":{"date-parts":[[2005,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Spondylarthropathies et m\u00e9dicaments anti-TNF\u03b1","name":"articletitle","label":"Article Title"},{"value":"La Revue de M\u00e9decine Interne","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.revmed.2005.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}